30 April 2020

Safety Warnings & Withdrawals of Medicines

Reference: CIR-2019-00000126

To all health facilities / all health care practitioners in Dubai's private health sector:

Referring to the above subject, DHA notes all health facilities regarding the Circular issued by the MOHAP for information and adhere to what is stated

• Adding warning for the pharmaceutical product containing the active ingredient of Tofacitinib 
• Add a warning to pharmaceuticals containing the active substance Febuxostat
• Withdrawal one batch of Pharmaceutical product Zypressin Injection (Vasopressin 20 IU)

Thanks in advance for your good co-operation

Drug Control Section

Health Regulation Sector

DHA

Supporting Documents:

إضافة تحذير على المستحضرات الدوائية الحاوية على المادة الفعالة Tofacitinib.pdf:

View Document

إضافة تحذير على المستحضرات الدوائية الحاوية على المادة الفعالة Febuxostat.pdf:

View Document

سحب تشغيلة واحدة من المستحضر الدوائي Zypressin Injection (Vasopressin 20 IU).pdf:

View Document